CA2539297C - Derives de triazoles substitues en tant qu'antagonistes de l'oxytocine - Google Patents

Derives de triazoles substitues en tant qu'antagonistes de l'oxytocine Download PDF

Info

Publication number
CA2539297C
CA2539297C CA2539297A CA2539297A CA2539297C CA 2539297 C CA2539297 C CA 2539297C CA 2539297 A CA2539297 A CA 2539297A CA 2539297 A CA2539297 A CA 2539297A CA 2539297 C CA2539297 C CA 2539297C
Authority
CA
Canada
Prior art keywords
compound
tautomer
triazol
methoxypyridin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2539297A
Other languages
English (en)
Other versions
CA2539297A1 (fr
Inventor
Alan Daniel Brown
Christopher Ronald Smith
David Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2539297A1 publication Critical patent/CA2539297A1/fr
Application granted granted Critical
Publication of CA2539297C publication Critical patent/CA2539297C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2539297A 2003-09-22 2004-09-10 Derives de triazoles substitues en tant qu'antagonistes de l'oxytocine Expired - Fee Related CA2539297C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0322159.5 2003-09-22
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0403150.6 2004-02-12
GB0415110.6 2004-07-05
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists
PCT/IB2004/002977 WO2005028452A1 (fr) 2003-09-22 2004-09-10 Derives de triazoles substitues en tant qu'antagonistes de l'oxytocine

Publications (2)

Publication Number Publication Date
CA2539297A1 CA2539297A1 (fr) 2005-03-31
CA2539297C true CA2539297C (fr) 2010-07-20

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2539297A Expired - Fee Related CA2539297C (fr) 2003-09-22 2004-09-10 Derives de triazoles substitues en tant qu'antagonistes de l'oxytocine

Country Status (12)

Country Link
EP (1) EP1673355A1 (fr)
JP (1) JP2007505888A (fr)
AR (1) AR045791A1 (fr)
BR (1) BRPI0414663A (fr)
CA (1) CA2539297C (fr)
MX (1) MXPA06003158A (fr)
NL (1) NL1027084C2 (fr)
PA (1) PA8613001A1 (fr)
PE (1) PE20050950A1 (fr)
TW (1) TW200526606A (fr)
UY (1) UY28524A1 (fr)
WO (1) WO2005028452A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
ES2399241T3 (es) * 2004-11-18 2013-03-26 Synta Pharmaceuticals Corporation Compuestos de triazol que modulan la actividad de HSP90
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
WO2006100588A1 (fr) * 2005-03-21 2006-09-28 Pfizer Limited Derives de triazole substitues utilises en tant qu'antagonistes d'oxytocine
NZ575514A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
WO2018113694A1 (fr) 2016-12-21 2018-06-28 江苏恒瑞医药股份有限公司 Dérivé de triazole du groupe azacyclobutyle à cycle condensé, son procédé de préparation et son utilisation en médecine
JP2020504109A (ja) 2016-12-28 2020-02-06 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． アザビシクロ置換トリアゾール誘導体、その調製方法、及びその医薬用途
CN111094272B (zh) * 2018-06-20 2022-05-27 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的***衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
WO2001058880A1 (fr) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
EP1293503A4 (fr) * 2000-05-19 2008-04-02 Astellas Pharma Inc Derives de triazole
ES2240661T3 (es) * 2001-07-05 2005-10-16 Pfizer Products Inc. Sulfonil-heteroaril-triazoles como agentes antiinflamatorios y analgesicos.
WO2003053437A1 (fr) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Triazoles utilises comme antagonistes de l'oxytocine

Also Published As

Publication number Publication date
JP2007505888A (ja) 2007-03-15
WO2005028452A1 (fr) 2005-03-31
PA8613001A1 (es) 2005-08-04
MXPA06003158A (es) 2006-06-05
NL1027084C2 (nl) 2006-01-24
BRPI0414663A (pt) 2006-11-21
CA2539297A1 (fr) 2005-03-31
PE20050950A1 (es) 2005-11-11
EP1673355A1 (fr) 2006-06-28
WO2005028452A9 (fr) 2005-07-21
NL1027084A1 (nl) 2005-03-24
AR045791A1 (es) 2005-11-16
UY28524A1 (es) 2005-04-29
TW200526606A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
US10150752B2 (en) Substituted triazole derivatives as oxytocin antagonists
WO2005082866A2 (fr) Derives de triazole substitues utilises en tant qu'antagonistes de l'oxytocine
CA2539297C (fr) Derives de triazoles substitues en tant qu'antagonistes de l'oxytocine
US20070185078A1 (en) Substituted triazole derivatives as oxytocin antagonists
US20080214622A1 (en) Substituted Triazole Derivatives As Oxytocin Antagonists
US20110092529A1 (en) 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists
US7875615B2 (en) Substituted triazole derivatives as oxytocin antagonists
CA2602198C (fr) Derives de triazole substitues en tant qu'antagonistes d'oxytocine
US20100222365A1 (en) Substituted triazole deriviatives as oxytocin antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed